I've led Sanofi’s General Medicine portfolio across Hong Kong and Taiwan, managing four leading brands that contribute over 50% of annual company revenue. I led the launch of Insultrate, Taiwan’s first digital therapeutic in diabetes care, and drove a GTM-model and commercial-structure transformation recognized with the Greater China President Award.
Previously, I built Dupixent’s launch momentum to more than 80% market share, expanded reimbursement access for pediatric patients, and created a shared decision-making tool that increased engagement by 30% in its first month. My background also includes product and marketing leadership across oncology, IV drugs, aesthetics medicine, medical devices, biomedical engineering, and life-science sales.
